| Literature DB >> 34045486 |
Arvind Gharbharan1, Carlijn C E Jordans1, Casper Rokx2, Bart J A Rijnders1, Corine GeurtsvanKessel1, Jan G den Hollander3, Faiz Karim4, Femke P N Mollema5, Janneke E Stalenhoef-Schukken6, Anthonius Dofferhoff7, Inge Ludwig8, Adrianus Koster9, Robert-Jan Hassing10, Jeannet C Bos11, Geert R van Pottelberge12, Imro N Vlasveld13, Heidi S M Ammerlaan14, Elena M van Leeuwen-Segarceanu15, Jelle Miedema1, Menno van der Eerden1, Thijs J Schrama1, Grigorios Papageorgiou1, Peter Te Boekhorst1, Francis H Swaneveld16, Yvonne M Mueller1, Marco W J Schreurs1, Jeroen J A van Kampen1, Barry Rockx1, Nisreen M A Okba1, Peter D Katsikis1, Marion P G Koopmans1, Bart L Haagmans1.
Abstract
In a randomized clinical trial of 86 hospitalized COVID-19 patients comparing standard care to treatment with 300mL convalescent plasma containing high titers of neutralizing SARS-CoV-2 antibodies, no overall clinical benefit was observed. Using a comprehensive translational approach, we unravel the virological and immunological responses following treatment to disentangle which COVID-19 patients may benefit and should be the focus of future studies. Convalescent plasma is safe, does not improve survival, has no effect on the disease course, nor does plasma enhance viral clearance in the respiratory tract, influence SARS-CoV-2 antibody development or serum proinflammatory cytokines levels. Here, we show that the vast majority of patients already had potent neutralizing SARS-CoV-2 antibodies at hospital admission and with comparable titers to carefully selected plasma donors. This resulted in the decision to terminate the trial prematurely. Treatment with convalescent plasma should be studied early in the disease course or at least preceding autologous humoral response development.Entities:
Year: 2021 PMID： 34045486 DOI： 10.1038/s41467-021-23469-2
Source DB: PubMed Journal: Nat Commun ISSN： 2041-1723 Impact factor: 14.919